Nuclear Medicine/Radiopharmaceuticals Market Share, Trends and Leading Players By 2023

New York, August 13, 2018: The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Cardinal Health, Inc. (U.S.), GE Healthcare (U.K.), Bracco Imaging S.p.A (Italy), Eczacibasi-Monrol Nuclear Products (Turkey), Nordion, Inc. (Canada), Advanced Accelerator Applications S.A. (France), Bayer Healthcare (Germany), Lantheus Medical Imaging, Inc. (U.S.), IBA Molecular Imaging (Belgium), and Mallinckrodt plc (Ireland).. Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.

Nuclear medicine is special category in medical branch used for diagnosis and treatment of disease in a safe and painless way. Nuclear medicine contain radioactive material which combined called as radiopharmaceutical. The small quantity of radiopharmaceutical is given into human body in the form of injection or swallowing. It goes to specific location of a body where there could be disease or abnormality. It emits radiation called gamma rays and contains gamma camera which helps nuclear medicine physician to see inside the body. It takes pictures of inner body which helps physician to diagnose patients’ disease.

The scope of the report includes a detailed study of global and regional markets for various types of nuclear medicine with the reasons given for variations in the growth of the industry in certain regions.

The nuclear medicine market is expected to exceed more than US$ 4.5 billion by 2021 growing at around 9.0% CAGR for the given forecast period.

Browser Full Report @:

The important factors driving the nuclear medicine market are advances in radiotracers and alpha radio immunotherapy-based targeted cancer treatment. SPECT and PET scans usage has been increasing to detect diseases like cancer which is driving the nuclear medicine market. Raising the incidence of cancer and cardiac ailments are also responsible for growing the nuclear medicine market. The nuclear medicine market is also having some restraints such as strict regulatory and global Good Manufacturing Practice guidelines. One of the major restraint is that most of the hospital still rely on conventional diagnostic procedures and not able to shift to nuclear medicine due to cost and availability issues. The life of radiopharmaceuticals is small so that sometimes the use of this is restricted.

The Nuclear Medicine Market has been segmented as below:

The Global Nuclear Medicine Market is segmented on the lines of Procedural Volume Segment Analysis, Type Analysis, Application Analysis and Regional Analysis. By Procedural Volume Segment Analysis this market is segmented on the basis of Diagnostics, SPECT Radiopharmaceuticals, PET Radiopharmaceuticals, Therapeutics, Beta Emitters, Alpha Emitters and Brachytherapy Isotopes. By Type Analysis this market is segmented on the basis of Diagnostics, SPECT Radiopharmaceuticals, Tc-99, Tl-201, Ga-67, I-123, PET Radiopharmaceuticals, F-18, Ru-82, Others, Therapeutics, Beta Emitters, I-131, Sm-153, Rh-186, Y-90, Lu-177, Others, Alpha, Emitters, Ra-223, Brachytherapy Isotopes, I-125, Ir-192, Pa-103, Cs-131 and Others.

By Application Analysis this market is segmented on the basis of Diagnostics, SPECT, Cardiology, Lymphoma, Thyroid, Neurology, Others, PET, Oncology, Cardiology, Neurology, Others, Therapeutics, Thyroid, Bone Metastasis, Lymphoma, Endocrine Tumors, Others. By Regional Analysis this market is segmented on the basis of North America, Europe, Asia-Pacific and Rest of the World.

This report provides:

1) An overview of the global market for nuclear medicine and related technologies.

2) Analyses of global market trends, with data from 2013, estimates for 2014 and 2015, and projections of compound annual growth rates (CAGRs) through 2021.

3) Identifications of new market opportunities and targeted promotional plans for nuclear medicine.

4) Discussion of research and development, and the demand for new products and new applications.

5) Comprehensive company profiles of major players in the industry.

Request Sample Report from here:


Table of Contents


2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Nuclear Medicine Market, By Type

7 Nuclear Medicine Market, By Application

8 Nuclear Medicine Market, By Procedural Volume

9 Global Nuclear Medicine Market, By Region

10 Global Nuclear Medicine Market, By Region

11 Competitive Landscape

11.1 Overview
11.2 Market Share Analysis

11.3 Competitive Situations and Trends
12 Company Profiles

12.1 Introduction

12.2 Cardinal Health, Inc.

12.3 Mallinckrodt PLC

12.4 GE Healthcare (A Fully Owned Subsidiary of General Electric Company)

12.5 Lantheus Medical Imaging, Inc.

12.6 Bayer AG

12.7 Bracco Imaging S.P.A

12.8 Eczacibasi-Monrol Nuclear Products

12.9 Nordion, Inc. (A Subsidiary of Sterigenics International LLC.)

12.10 Advanced Accelerator Applications S.A.

12.11 IBA Molecular


Media Contact

Company Name: Market Research Engine

Contact Person: John Bay

Email: [email protected]

Phone: +1-855-984-1862

Country: United States





The post Nuclear Medicine/Radiopharmaceuticals Market Share, Trends and Leading Players By 2023 appeared first on Herald Keeper.

Add Comment